Clinical trials: Metastatic Adenocarcinoma
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
In this study, Erlotinib and 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (a regimen known also as FOLFOX-6) will be the chemotherapy study drugs.
- Conditions
- Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
- Trial name
- NCT00591123
- Testing
- FOLFOX, 5-FU, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Translational Oncology Research International
Adenocarcinoma
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
This study is a multicenter non-interventional observational retrospective study with secondary data collection
- Trial name
- NCT05892926
- Where
- 31 sites in Russia
- Volunteers
- 204 people
- Sponsor
- AstraZeneca
Nanoliposomal Irinotecan, Cadonilimab
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal…
- Conditions
- Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine
- Trial name
- NCT06405490
- Testing
- Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Neuroendocrine Tumors
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Prospective phase 2a clinical trial to demonstrate proof-of-concept for simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG for positron emission tomography (PET) and MRS (magnetic resonance spectroscopy) in a PET/MR scanner…
- Conditions
- Breast Cancer, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic
- Trial name
- NCT05396118
- Testing
- 18F-FDG, Injection of hyperpolarized [1-13C]Pyruvate, PET/MR/MRS/MRSI scanning
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
- Trial name
- NCT01298323
- Testing
- Patient outreach, Vandetanib
- Where
- 66 sites in Australia, Austria and 18 more
- Volunteers
- 205 people
- Sponsor
- Sanofi
Biliary Tract Adenocarcinoma
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
The prospective, multicenter, single-arm design study is to evaluate the efficacy and safety of fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who failed first-line chemotherapy with…
- Trial name
- FSTAMBTA (NCT04156958)
- Testing
- Fruquintinib
- Where
- 7 sites in China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether fluorouracil and leucovorin plus irinotecan is more effective than fluorouracil…
- Trial name
- NCT00004885
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 57 sites in Austria, Belgium and 7 more
- Volunteers
- 430 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other…
- Conditions
- Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03678025
- Testing
- Abiraterone, Bicalutamide, Degarelix
- Where
- 338 sites in United States, Chile and 3 more
- Volunteers
- 1,273 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
The study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activates the immune system to fight cancer, and olaparib destroys cancer cells by…
- Trial name
- NCT04666740
- Testing
- Pembrolizumab, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 63 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
- Trial name
- NCT05479578
- Testing
- Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rashmi Verma, MD
Esophageal Cancer
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00109850
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- 132 sites in United States
- Volunteers
- 22 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
Background: It is estimated that in the Netherlands each year approximately 900 patients with gastric cancer or adenocarcinoma of the gastro-oesophageal junction are candidates for chemotherapy.
- Trial name
- B-DOCT (NCT01359397)
- Testing
- Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Gastrointestinal Neoplasm, Gastric Adenocarcinoma
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.
- Trial name
- IXOGoo1 (NCT01129310)
- Testing
- Irinotecan-Capecitabine-Oxaliplatin
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- AHS Cancer Control Alberta
Metastatic Renal Cell Carcinoma
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on…
- Trial name
- SPAZO (NCT02282579)
- Testing
- Pazopanib
- Where
- 34 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
This phase II trial is studying how well giving bortezomib together with carboplatin works in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Trial name
- NCT00416793
- Testing
- bortezomib, carboplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
The present study aims to optimize the use of systemic therapy relative to local tumor ablation in a prospective randomized clinical trial and to validate the existence and characterize the clinical and pathology phenotype of…
- Trial name
- NCT04031378
- Testing
- Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation, Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Fundacao Champalimaud